Text size :

Non-profit cancer research, Di Maio (Aiom): “More funds needed for independent studies”

ADNKRONOS

November 15, 2026

Rome, Nov 15. (Adnkronos Health) – “Aiom strongly urges institutions to support independent academic research in our country. Trials promoted by pharmaceutical companies represent great value, as they allow innovative drugs to be brought to treatment centers and made available to patients. But they are only one part of the system. In addition to attracting industry-funded studies, we must be able to produce quality independent research, as has happened for many decades in the Italian tradition. In our country, there are cooperative groups of excellence, gathered in the Italian Federation of Cooperative Oncology Research Groups (Ficog)”. This was stated by Massimo Di Maio, Aiom president, speaking at the press conference on non-profit clinical studies in Italy, as part of the XXVIII national congress of the Italian Association of Medical Oncology, which concludes today in Rome.

“Today – explains Di Maio – conducting an academic study can be very difficult. Funding and personnel dedicated to management are needed, especially when it comes to trials involving multiple centers. It is not possible to carry out these projects with insufficient resources. There are also regulatory and organizational obstacles. For example, if we want to verify whether a lower dose of an already approved drug is equally effective, and perhaps also allows for savings, we cannot use the drug available for normal clinical practice, because the study involves a different dosage than the authorized one. Without specific funding, therefore, the trial risks not being carried out.”

Another fundamental contribution of independent research concerns the comparison between different drugs used for the same disease. “In oncology, in fact, we don’t always know which is the best treatment, because there are often no studies that directly compare different therapies. An example is the Fata study, whose results are presented at the congress by the group coordinated by the president of the Aiom Foundation, Francesco Perrone. Thanks to Aifa funding – Di Maio emphasizes – the study compared three different drugs used in adjuvant hormonal therapy for breast cancer. This is research that a pharmaceutical company would hardly have promoted, because it would not have had an interest in directly comparing its drugs with competing ones. Academic research, on the other hand, carried out a study on a large number of patients, producing useful results for clinical practice.” Research funded “by pharmaceutical companies is important, but we cannot do without independent research, because it answers different questions that would otherwise risk remaining unanswered. For example, companies may not be interested in verifying whether a lower dose of a drug is equally effective or in identifying which patients truly benefit from an already approved therapy. These are questions that often do not fall within the objectives of industrial research and must therefore be addressed by independent academic research,” he concluded.

Jiji Press

Related

Page TOP